+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Medicaid prior authorization policies and imprisonment among patients with schizophrenia



Medicaid prior authorization policies and imprisonment among patients with schizophrenia



American Journal of Managed Care 20(7): 577-586



To examine the impact of Medicaid prior authorization for atypical antipsychotics on the prevalence of schizophrenia among the prison population. Study We collected drug-level information on prior authorization restrictions from Medicaid programs in 30 states to determine which states had prior authorization requirements before 2004. We linked the regulatory data to a survey of prison inmates conducted in 2004. We used a sample of 16,844 inmates from a nationally representative survey and analyzed the data using cross-sectional regression. To capture the impact of prior authorization, we estimated 2 models: the first included an indicator variable for states requiring prior authorization, and a second model used per capita atypical usage. Evidence indicated that prior authorization restrictions on atypical antipsychotics are associated with an increase in the odds of a schizophrenic resident being imprisoned in a state. State-level prior authorization requirements for atypical antipsychotics are associated with a 2.7% increase in the likelihood that an imprisoned inmate displays psychotic symptoms, and a 1.25 increase in the likelihood that an inmate was previously diagnosed with schizophrenia by a physician. Higher state-level atypical prescriptions per capita are also associated with lower likelihood of psychotic symptoms and of prior schizophrenia diagnosis among prisoners. Prior authorization requirements for atypical antipsychotics, which are designed to reduce healthcare costs, are associated with greater prevalence of mental illness within the criminal justice system.This association raises important questions about whether increased costs to the criminal justice system might mitigate or offset prescription drug savings created by prior authorization requirements.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 054305171

Download citation: RISBibTeXText

PMID: 25295404


Related references

Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study. Clinical Therapeutics 32(4): 729-41; Discussion 716, 2010

Medicaid prior authorization policies for pediatric use of antipsychotic medications. JAMA 313(9): 966-968, 2015

Do prior authorization policies discourage first-line antipsychotic use in patients newly discharged from a hospitalization for schizophrenia in Saskatchewan?. Journal of Population Therapeutics and Clinical Pharmacology 21(1): E31-E37, 2014

Prior Authorization Policies for Selective Cyclooxygenase-2 Inhibitors in Medicaid: A Policy Review. Medical Care 44(7): 658-663, 2006

Prior authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid: a policy review. Medical Care 44(7): 658-663, 2006

Development of the burden of prior authorization of psychotherapeutics (BoPAP) scale to assess the effects of prior authorization among Texas Medicaid providers. Administration and Policy in Mental Health 36(4): 278-287, 2009

Prior authorization policies in Medicaid programs: The importance of study design and analysis on findings and outcomes from research. Research in Social and Administrative Pharmacy 12(1): 154-163, 2016

The effects of prior authorization policies on medicaid-enrolled children's use of antipsychotic medications: evidence from two mid-Atlantic states. Journal of Child and Adolescent Psychopharmacology 24(7): 374-381, 2014

Economic impact of prior authorization policies for atypical antipsychotics in the treatment of schizophrenia. Population Health Management 13(5): 247-254, 2010

Association Between Prior Authorization for Medications and Health Service Use by Medicaid Patients With Bipolar Disorder. Yearbook of Psychiatry and Applied Mental Health 2012: 194-195, 2012

Assessing the impact of a medicaid prior authorization (Pa) policy for duloxetine on antipsychotic use among patients with depression. Value in Health 16(3): A68-A69, 2013

Association between prior authorization for medications and health service use by Medicaid patients with bipolar disorder. Psychiatric Services 62(2): 186-193, 2011

Medicaid and the unconstitutional dimensions of prior authorization. Michigan Law Review 101(2): 602-647, 2002

Medicaid prior authorization and controlled-release oxycodone. Medical Care 46(6): 573-580, 2008

Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. New England Journal of Medicine 351(21): 2187-2194, 2004